TriangleDISEASE & TREATMENT SETTING
OPDIVO QVANTIG: metastatic gastric cancer with PD-L1 stated without a specific alteration
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
1.12 Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma OPDIVO QVANTIG, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.2) ] .
Broader topic: Gastric Cancer
- Source population
- Not part of this definition
- Disease extent
- metastatic
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- gene
- PD-L1
- alteration
- stated without a specific alteration
- status
- present
- prior therapy
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for OPDIVO QVANTIG (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- 1.12 Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma OPDIVO QVANTIG, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.2) ] .
Study evidence for this setting
No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice